Is Gabapentin (Neurontin) Safe with Ketamine?

If you're on Gabapentin (Neurontin) and considering at-home ketamine therapy, the combination is safe at all standard dose ranges. The most important thing to know up front is that despite gabapentin's name and its widespread use for anxiety, gabapentin is not pharmacologically related to the benzodiazepine class and does not produce the documented attenuation of ketamine's antidepressant response that benzos do. The verdict is straightforward: continue gabapentin throughout your ketamine course, with brief attention to sedation timing at higher doses.

Why the name is misleading

The gabapentin name suggests GABA, the inhibitory neurotransmitter that benzodiazepines and Z-drugs work on. The drug was originally designed as a GABA analog, hence the name. But in the actual brain, gabapentin doesn't bind GABA receptors. It instead modulates the alpha-2-delta subunit of voltage-gated calcium channels, reducing presynaptic neurotransmitter release in certain neural pathways. The clinical effects (analgesia, anxiolysis, anticonvulsant action) come from this calcium-channel modulation rather than from any direct GABA receptor activity.

This is the most clinically important point on this page for ketamine therapy purposes. The Veraart 2021 systematic review's recommendation to "minimize benzodiazepine (and Z-drug) use in patients receiving ketamine for depression" is mechanism-specific: it applies to drugs that bind the GABA-A benzodiazepine receptor and dampen glutamate signaling. Gabapentin doesn't fit that mechanism category. The attenuation concern that drives the Xanax, Klonopin, and Ambien intake conversations does not apply to gabapentin in the same way.

What gabapentin is actually used for

Gabapentin's FDA-approved indications are: postherpetic neuralgia (chronic nerve pain after shingles), partial-onset seizures (as adjunctive therapy), restless legs syndrome (the gabapentin enacarbil formulation, Horizant). Off-label use is widespread and clinically important: diabetic peripheral neuropathy, fibromyalgia, generalized anxiety disorder (one of the most common off-label uses), insomnia, alcohol withdrawal, migraine prophylaxis, postoperative pain, and various other neuropathic pain conditions.

In practice, the patients we see on gabapentin at Tovani fall into several patterns: chronic pain patients (often with co-occurring depression that's the reason they're considering ketamine), anxiety patients (gabapentin is increasingly prescribed as a benzo alternative, especially in patients with substance use history), insomnia patients (off-label, often after Ambien hasn't worked or is being tapered), and occasionally seizure-prophylaxis patients.

What the published evidence shows

The general antidepressant + ketamine evidence base applies in full to patients on gabapentin. The Veraart 2021 systematic review (PMID 34170315) did not identify gabapentin or other gabapentinoids as a documented case-series risk and did not extend its benzo/Z-drug minimization recommendation to gabapentin. The Curran 2026 outcomes study (DOI 10.4088/JCP.25br16294) included gabapentin-treated patients without reporting differential outcomes. The Alnefeesi 2022 real-world meta-analysis (PMID 35688035) pooled 2,665 TRD patients with gabapentin commonly prescribed in the chronic-pain-and-depression population; pooled response and remission rates of 45% and 30% include this population.

No gabapentin-specific case reports of serotonin syndrome, hypertensive crisis, or other adverse outcomes from at-home ketamine combination exist in the published literature.

For the seizure-threshold question: gabapentin is used for focal seizure prophylaxis, and ketamine at therapeutic at-home doses has an anticonvulsant rather than pro-convulsant profile per the Shehata 2024 systematic review (PMID 38293492). Combining the two does not compound seizure risk; both work in the seizure-protective direction.

The sedation-timing note

Gabapentin can be meaningfully sedating, particularly at higher doses (1800 mg/day and above) and in the first few hours after a dose. For patients on standard low-to-moderate doses (300-900 mg/day total, typically split into 3 times daily), the sedation is usually mild and doesn't require timing adjustment for ketamine sessions. For patients on high doses (1800-3600 mg/day, common in chronic pain), the sedation can be more substantial and we suggest scheduling daytime ketamine sessions for late morning or early afternoon, after the morning dose has cleared but before the next dose.

For patients using gabapentin only at bedtime (off-label for insomnia), the sedation is overnight and morning sessions don't require timing adjustment.

What we do at intake

When a patient is on gabapentin, our intake process for ketamine includes:

The total daily dose. 100 mg to 3600 mg/day depending on indication.

The dosing schedule. Once daily (rare), twice daily (occasional), three times daily (most common at therapeutic doses), or as-needed (for some pain or anxiety indications).

The indication. Chronic neuropathic pain, fibromyalgia, anxiety, insomnia, seizure prophylaxis, restless legs, alcohol withdrawal recovery, or other.

How long you've been on the current dose. Stable for at least 4-6 weeks is most common.

The prescribing physician relationship. For chronic pain or seizure indications, we coordinate with the prescribing physician.

For most patients on stable gabapentin, this is a brief conversation and we proceed with standard ketamine onboarding.

Tapering: not for ketamine

Long-term gabapentin use produces tolerance, and abrupt stopping at high doses can produce rebound symptoms including the return of pain or anxiety, sleep disturbance, and rarely seizures. There is no reason to taper gabapentin for ketamine purposes. Tapering decisions belong with your prescribing physician on their own clinical merits.

For patients using gabapentin for anxiety as a benzo alternative, ketamine treatment may eventually allow a coordinated reduction (similar to the Ambien-and-depression-driven-insomnia pattern), but this is a longer-term conversation rather than a precondition.

Bottom line

Gabapentin at all standard doses is safe to combine with at-home ketamine therapy. The mechanism is fundamentally different from benzodiazepines and Z-drugs (alpha-2-delta calcium channel modulation, not GABA-A binding), so the documented benzo attenuation of ketamine response does not apply. The only operational consideration is sedation timing at higher doses, which is straightforward to accommodate. Continue your current gabapentin regimen throughout the ketamine course.